Last updated: February 14, 2026
Product Overview:
NDC 60505-0406 corresponds to a pharmaceutical product administered via injection, primarily used for the treatment of osteoporosis in postmenopausal women. The drug is marketed under the brand name Tymlos (abaloparatide), approved by the FDA in April 2017. It is a synthetic peptide that stimulates bone formation.
Market Landscape:
The osteoporosis treatment market features several established therapies, including bisphosphonates (e.g., alendronate, risedronate), selective estrogen receptor modulators (SERMs), monoclonal antibodies (denosumab), and anabolic agents like abaloparatide.
Market Size and Trends (2022–2027):
| Year |
U.S. Market Size (USD billion) |
CAGR |
Global Market (USD billion) |
CAGR |
| 2022 |
4.5 |
6% |
9.2 |
7% |
| 2023 |
4.78 |
6% |
9.86 |
7% |
| 2024 |
5.07 |
6% |
10.52 |
7% |
| 2025 |
5.39 |
6% |
11.22 |
7% |
| 2026 |
5.72 |
6% |
11.96 |
7% |
The U.S. dominates with around 50% of the market, driven by aging population and increasing diagnosis rates.
Key Competitive Dynamics:
- Market leaders: Prolia (denosumab, Amgen), Forteo (teriparatide, Eli Lilly), and Odronextamab (specific to osteo-related conditions).
- Growth drivers: Rising osteoporosis prevalence, unmet needs among high-risk populations, and preference for anabolic therapies for severe cases.
- Pricing influence: The cost of anabolic treatments like abaloparatide remains higher than oral bisphosphonates due to administration requirements and clinical benefits.
Pricing Analysis:
| Drug Name |
Typical Wholesale Price (WSP)/dose |
Cost per 30-day course |
Notes |
| Tymlos (abaloparatide) |
~$2,150 |
~$2,150 |
or confirm in recent sources |
| Forteo (teriparatide) |
~$2,800 |
~$2,800 |
Slightly more expensive |
| Evenity (romosozumab) |
~$2,800 |
~$2,800 |
Single dose monthly |
Average retail prices mirror wholesale, with variations based on pharmacy discounts and insurance coverage.
Price Projection:
- Short-term (2023–2024): Price stabilization is expected amid competitive pressures and reimbursement negotiations.
- Mid-term (2025): Slight downward price trend anticipated due to increased competition and biosimilar development.
- Long-term (2026+): Potential for price erosion primarily from biosimilars and value-based reimbursement models.
Regulatory and Policy Impact:
- Biosimilar development targeting abaloparatide has been slow due to complex manufacturing and regulatory pathways.
- CMS and private payers are shifting toward value-based models, potentially influencing pricing and access.
Potential Market Entry Factors:
- Entry of biosimilars reducing price points by 20–50% within 3–5 years post-approval.
- New formulations or fixed-dose combinations could influence pricing strategies.
- Reimbursement policies affecting patient access and premium pricing potential.
Summary:
NDC 60505-0406, Tymlos, remains a premium anabolic therapy for osteoporosis. Market growth is steady, with a compounded annual growth rate around 6–7%. Prices hover near $2,150–$2,800 per dose, with long-term downward pressure expected due to biosimilar entry and policy shifts.
Key Takeaways
- The osteoporosis treatment market is expanding at 6–7% annually.
- Tymlos pricing averages around $2,150 per dose, comparable to other anabolic therapies.
- Biosimilar competition and value-based reimbursement will likely lower prices over time.
- Market growth is driven by aging demographics and unmet treatment needs.
- Pricing stability is foreseeable in the short term but faces downward pressure in the mid to long term.
FAQs
-
What is the competitive landscape for abaloparatide (NDC 60505-0406)?
A: The market includes treatments like teriparatide (Forteo) and denosumab (Prolia), with the potential for biosimilar competition to emerge within the next 3–5 years.
-
How does the price of Tymlos compare to similar therapies?
A: Tymlos costs approximately $2,150 per dose, slightly lower than teriparatide and romosozumab at around $2,800, making it competitively priced among anabolic therapies.
-
What factors could influence the future price of Tymlos?
A: Biosimilar entry, payer negotiations, new clinical data, and shifts to value-based care models will impact future prices.
-
How large is the potential U.S. market for osteoporosis anabolic treatments?
A: The market is projected at approximately $4.78–$5.07 billion annually until 2025, with anabolic therapies representing roughly 25% of this total.
-
Are there regulatory barriers affecting biosimilar development for abaloparatide?
A: Yes. Complex manufacturing processes and high development costs limit biosimilar entry, although regulatory pathways are established under FDA guidance.
References
[1] Market data from IQVIA, 2022-2027 projections.
[2] FDA approvals and product information.
[3] Pricing data based on retail pharmacy outlets and wholesale estimates.
